With a growing body of evidence demonstrating the central role of YAP/TAZ dysregulation in promoting tumorigenesis, and especially aggressive tumor phenotypes, targeted therapies that inhibit their functions may yield significant therapeutic efficacy. Here, WWTR1 is linked to neoplasm.